About Vertex Pharmaceuticals Incorporated
https://www.vrtx.comVertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis.
CEO
Reshma Kewalramani FASN,
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2000-08-24 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 927
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
UBS
Buy
Citigroup
Buy
Guggenheim
Buy
Truist Securities
Buy
HC Wainwright & Co.
Buy
B of A Securities
Buy
Grade Summary
Showing Top 6 of 20
Price Target
Institutional Ownership
CAPITAL WORLD INVESTORS
Shares:25.91M
Value:$11.65B
VANGUARD GROUP INC
Shares:24.22M
Value:$10.89B
BLACKROCK, INC.
Shares:22.25M
Value:$10B
Summary
Showing Top 3 of 1,969
About Vertex Pharmaceuticals Incorporated
https://www.vrtx.comVertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $3.08B ▲ | $1.48B ▲ | $1.08B ▲ | 35.2% ▲ | $4.24 ▲ | $1.36B ▲ |
| Q2-2025 | $2.96B ▲ | $1.41B ▼ | $1.03B ▲ | 34.84% ▲ | $4.02 ▲ | $1.34B ▲ |
| Q1-2025 | $2.77B ▼ | $1.78B ▲ | $646.3M ▼ | 23.33% ▼ | $2.52 ▼ | $781.8M ▼ |
| Q4-2024 | $2.91B ▲ | $1.46B ▲ | $913M ▼ | 31.35% ▼ | $3.55 ▼ | $1.18B ▼ |
| Q3-2024 | $2.77B | $1.26B | $1.05B | 37.71% | $4.05 | $1.28B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $6.29B ▼ | $24.86B ▲ | $7.54B ▲ | $17.32B ▲ |
| Q2-2025 | $6.38B ▲ | $24.04B ▲ | $6.86B ▲ | $17.18B ▲ |
| Q1-2025 | $6.2B ▲ | $22.88B ▲ | $6.38B ▲ | $16.5B ▲ |
| Q4-2024 | $6.12B ▼ | $22.53B ▲ | $6.12B ▼ | $16.41B ▲ |
| Q3-2024 | $6.52B | $22.24B | $6.61B | $15.63B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.08B ▲ | $1.24B ▲ | $-117M ▲ | $-1.15B ▼ | $-34.2M ▼ | $1.14B ▲ |
| Q2-2025 | $1.03B ▲ | $1.07B ▲ | $-484.5M ▼ | $-349.2M ▲ | $296.6M ▲ | $927.4M ▲ |
| Q1-2025 | $646.3M ▼ | $818.9M ▲ | $-55.8M ▲ | $-680.4M ▼ | $113.2M ▲ | $778.2M ▲ |
| Q4-2024 | $913M ▼ | $584.6M ▼ | $-821.9M ▼ | $-391.3M ▼ | $-675.9M ▼ | $492M ▼ |
| Q3-2024 | $1.05B | $1.37B | $-348M | $-387.5M | $657.1M | $1.3B |
Revenue by Products
| Product | Q4-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 ALYFTREK | $0 ▲ | $250.00M ▲ | $160.00M ▼ | $50.00M ▼ |
 Manufactured Product Other | $590.00M ▲ | $180.00M ▼ | $240.00M ▲ | $170.00M ▼ |
 TRIKAFTAKAFTRIO | $2.72Bn ▲ | $2.65Bn ▼ | $2.55Bn ▼ | $2.54Bn ▼ |
Revenue by Geography
| Region | Q4-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 Europe | $830.00M ▲ | $840.00M ▲ | $910.00M ▲ | $830.00M ▼ |
 NonUS | $0 ▲ | $1.36Bn ▲ | $0 ▼ | $0 ▲ |
 Other NonUS | $240.00M ▲ | $0 ▼ | $210.00M ▲ | $280.00M ▲ |
 UNITED STATES | $1.84Bn ▲ | $1.98Bn ▲ | $1.83Bn ▼ | $1.65Bn ▼ |
CEO
Reshma Kewalramani FASN,
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2000-08-24 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 927
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
UBS
Buy
Citigroup
Buy
Guggenheim
Buy
Truist Securities
Buy
HC Wainwright & Co.
Buy
B of A Securities
Buy
Grade Summary
Showing Top 6 of 20
Price Target
Institutional Ownership
CAPITAL WORLD INVESTORS
Shares:25.91M
Value:$11.65B
VANGUARD GROUP INC
Shares:24.22M
Value:$10.89B
BLACKROCK, INC.
Shares:22.25M
Value:$10B
Summary
Showing Top 3 of 1,969